Biomarkers and outcomes for pembrolizumab/axitinib for kidney cancer

In this phase 1b study, he researchers were looking for a relationship between biomarkers found in the blood and outcomes following treatment with a combination pembrolizumab plus axitinib for advanced renal cell carcinoma (RCC). They found that high levels of a T cell protein receptor called CD8 in the kidney tumour at baseline were associated […]

read more

Ipilimumub plus nivolumab combination after prior treatment with immune checkpoint inhibitors

This retrospective study published in the Journal of Clinical Oncology looked at the response rates and progression-free survival of metastatic renal cell carcinoma (RCC) patients treated with a combination of ipilimumab plus nivolumab after previous treatment with an immune checkpoint inhibitor. Forty-five patients with metastatic RCC who had already been treated with an immune checkpoint […]

read more

Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab

In a paper published in Clinical Genitourinary Cancer the link between immune-related adverse events and clinical outcomes in patients with metastatic renal cell carcinoma (RCC) was investigated. One hundred and sixty seven (167) patients were included in the study. Of these, 46% had an immune-related adverse event, of which 8.9% were severe or life-threatening. However, […]

read more

ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

Results from a phase II international trial led by researchers at MD Anderson Cancer Center in America were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial showed treatment with a novel hypoxia inducible factor (HIF)-2 alpha inhibitor (MK-6482) was well tolerated and resulted in clinical responses in patients with von […]

read more

First-line immunotherapy combination treatments for metastatic kidney cancer

A meta-analysis of four major clinical trials of immunotherapy combinations for the first-line treatment of metastatic renal cell carcinoma (RCC) was published in the journal Clinical Genitourinary Cancer earlier this month. The analysis compared progression-free survival, overall survival and objective response rate from four major clinical trials: CheckMate 214 (nivolumab/ipilimumab vs sunitinib), Keynote-426 (pembrolizumab/axitinib vs […]

read more

Axitinib first-line treatment of papillary renal cell carcinoma

The majority of renal cell carcinomas (RCCs) are a subtype called clear cell RCC. Most drugs have been developed to treat this subtype of RCC, leaving people with other metastatic RCC subtypes with an unmet need for an effective treatment in the first-line. Papillary RCC (pRCC) represents 10-15% of renal cell carcinomas, and is not an insignificant subtype. […]

read more

Novel HIF-2a inhibitor for patients with advanced kidney cancer

In this interview with Practice Update, Dr Eric Jonasch from MD Anderson Cancer Center in the USA talks about the the novel hypoxia inducible factor (HIF)-2 alpha inhibitor for the treatment of previously treated advanced renal cell carcinoma (RCC). Dr Jonasch described how HIF-2 alpha works and then went on to talk about the results […]

read more

ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab

Five-year follow-up results from the phase 3 CheckMate-025 study, which compared nivolumab (Opdivo) with everolimus in previously treated advanced or metastatic renal cell carcinoma (RCC), were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. Nivolumab continues to show superior overall survival and objective response rates […]

read more

Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone

A recent phase II clinical trial has shown that combined use of a PD-1 inhibitor and a PD-L1 inhibitor proved no more beneficial than anti-PD-1 treatment alone in metastatic renal cell carcinoma (RCC) patients who had already been treated with targeted therapy. There was no significant difference in the primary endpoint of the study, which […]

read more
Showing all 9 results
  TOP